

Q3 2021 Non-GAAP Reconciliations

November 8, 2021



Non-GAAP Financial Measures

This presentation includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("U.S. GAAP"). These non-GAAP financial measures, including, but not limited to, adjusted gross profit, adjusted gross margins, adjusted net earnings, EBITDA, adjusted EBITDA margin, adjusted EBITDA, free cash flow, adjusted R&D and as a % of total revenues, adjusted SG&A and as a % of total revenues, adjusted earnings from operations, adjusted interest expense, adjusted other (income) expense, adjusted effective tax rate, constant currency total revenues and constant currency net sales are presented in order to supplement investors' and other readers' understanding and assessment of the financial performance of Viatris Inc. ("Viatris" or the "Company"). Free cash flow refers to U.S. GAAP net cash provided by operating activities, less capital expenditures. Adjusted EBITDA margins refers to adjusted EBITDA divided by total revenues. Viatris has provided reconciliations of such non-GAAP financial measures to the most directly comparable U.S. GAAP financial measures. Investors and other readers are encouraged to review the related U.S. GAAP financial measures and the reconciliations of the non-GAAP measures to their most directly comparable U.S. GAAP measures set forth in this presentation and in the section titled "GAAP/Non-GAAP Reconciliations", and investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with U.S. GAAP.



Viatris Inc. and Subsidiaries

Full Year 2021 Guidance Items

(Unaudited; in millions)

	GAAP	Non-GAAP
Total Revenues	\$17,700 - \$17,900	N/A
Adjusted EBITDA	N/A	\$6,300 - \$6,500
Net Cash provided by Operating Activities	\$2,900 - \$3,100	N/A
Free Cash Flow	N/A	\$2,400 - \$2,600

Viatris Inc. and Subsidiaries

Reconciliation of Estimated 2021 GAAP Net Cash Provided by Operating Activities to Free Cash Flow (Unaudited; in millions)

\$2,900 - \$3,100
(450) - (550)
\$2,400 - \$2,600



Adjusted Net Earnings

(In millions)		ree Mont Septem			Nine Months Ended September 30,		
		2021		2020		2021	2020
U.S. GAAP net earnings (loss)	\$	311.5	\$	185.7	\$ ((1,005.3) \$	245.9
Purchase accounting related amortization (primarily included in cost of sales) (a)		919.9		368.5		3,344.7	1,072.5
Litigation settlements and other contingencies, net		9.4		18.9		55.3	36.5
Interest expense (primarily amortization of premiums and discounts on long term debt)		(13.6)		5.3		(40.3)	16.6
Clean energy investments pre-tax loss		17.6		2.9		52.2	37.4
Acquisition related costs (primarily included in SG&A) (b)		41.5		72.3		149.7	218.2
Restructuring related costs (c)		169.8		14.5		741.6	47.0
Share-based compensation expense		25.0		15.1		88.7	49.8
Other special items included in:							
Cost of sales (d)		72.7		83.6		257.1	299.3
Research and development expense (e)		3.7		3.7		12.1	45.8
Selling, general and administrative expense		9.9		7.5		39.4	12.9
Other expense, net		(2.3)		-		(2.3)	(16.4)
Tax effect of the above items and other income tax related items (f)		(366.0)		(98.3)		(196.8)	(344.3)
Adjusted net earnings	\$	1,199.1	\$ (679.7	\$	3,496.1 \$	1.721.2

⁽a) For the three and nine months ended September 30, 2021, includes amortization of the purchase accounting inventory fair value adjustment related to the Combination totaling approximately \$238.5 million and \$1.19 billion, respectively. (b) Acquisition related costs consist primarily of transaction costs including legal and consulting fees and integration activities.

⁽f) Adjusted for changes for uncertain tax positions and for certain impacts of the Combination.



⁽c) For the three months ended September 30, 2021, charges of approximately \$15.1.3 million are included in Cost of sales, approximately \$4.7) million are included in R&D, and approximately \$23.1 million are included in SG&A. For the nine months ended September 30, 2021 charges of approximately \$11.9 million are included in SG&A.

⁽d) Costs incurred during the three and nine months ended September 30, 2021 include incremental manufacturing variances and site remediation activities as a result of the activities at the Company's Morgantown plant of approximately \$1.8 million and \$107.3 million, respectively, and at other plants in the 2020 restructuring program of approximately \$4.10 million and \$107.8 million, and \$107.6 million, respectively. Costs incurred during the three and nine months ended September 30, 2020 include incremental manufacturing variances and site remediation activities as a result of the activities at the Company's Morgantown plant of approximately \$57.8 million and \$179.6 million, respectively. Addition, the three and nine months ended September 30, 2020 includes incremental manufacturing variances incurred as a result of the COVID-19 pandemic of approximately \$8.0 million and \$32.0 million, respectively. Also, the nine months ended September 30, 2020 includes \$27.0 million related to a special bonus for plant employees as a result of the COVID-19 pandemic.

⁽e) Adjustments primarily relate to non-refundable payments related to development agreements.

Net Earnings (Loss) to Adjusted EBITDA

	Three Months	s Ended	Nine Months	Ended
	Septembe	er 30,	Septembe	r 30,
(In millions)	2021	2020	2021	2020
U.S. GAAP net earnings (loss)\$	311.5 \$	185.7 \$	(1,005.3) \$	245.9
Add adjustments:				
Net contribution attributable to equity method investments	17.6	2.9	52.2	37.4
Income tax (benefit) provision	(111.6)	55.9	544.8	46.4
Interest expense (a)	151.9	117.3	488.0	353.4
Depreciation and amortization (b)	1,017.1	432.3	3,756.7	1,263.0
ЕВПОА\$	1,386.5 \$	794.1 \$	3,836.4 \$	1,946.1
Add adjustments:				
Share-based compensation expense	25.0	15.1	88.7	49.8
Litigation settlements and other contingencies, net	9.4	18.9	55.3	36.5
Restructuring, acquisition related and other special items (c)	277.4	181.6	1,029.9	606.6
Adjusted EBITDA\$	1,698.3 \$	1,009.7 \$	5,010.3 \$	2,639.0

c) See items detailed in the Reconciliation of U.S. GAAP Net Earnings (Loss) to Adjusted Net Earnings.



Includes amortization of premiums and discounts on long-term debt.

b) Includes purchase accounting related amortization.

Summary of Total Revenues by Segment

				Three Months September		
_			2021	Currency Impact	2021 Constant Currency	
(In millions, except %s)	2021	2020	% Change	(1)	Revenues	Constant Currency % Change (2)
Net sales						
Developed Markets \$	2,655.9 \$	2,163.2	23 % \$	(17.3) \$	2,638.4	22 %
Greater China	566.8	31.5	nm	(0.3)	566.6	nm
JANZ	505.3	282.4	79 %	2.5	507.9	80 %
Emerging Markets	792.5	471.0	68 %	(6.2)	786.3	67 %
Total net sales	4,520.5	2,948.1	53 %	(21.3)	4,499.2	53 %
Other revenues (3)	16.1	24.0	(33)%	-	16.1	(33)%
Consolidated total revenues (4) \$	4,536.6 \$	2,972.1	53 % <u>\$</u>	(21.3) \$	4,515.3	52 %
				Nine Months E	Inded	
				Nine Months E September		
_				September Currency Impact	30, 2021 Constant Currency	
· —	2021	2020	2021 % Change	September	30,	Constant Currency % Change (2)
Net sales	-		% Change	September Currency Impact	30, 2021 Constant Currency Revenues	· · · · · ·
Net sales Developed Markets\$	7,867.9 \$	6,132.3		September Currency Impact	30, 2021 Constant Currency Revenues 7,641.4	Constant Currency % Change (2) 25 %
Net sales Developed Markets\$ Greater China	7,867.9 \$ 1,709.0	6,132.3 69.3	% Change 28 % \$ nm	September Currency Impact	30, 2021 Constant Currency Revenues 7,641.4 1,708.4	25 % nm
Developed Markets\$ Greater China JANZ	7,867.9 \$ 1,709.0 1,488.2	6,132.3	% Change 28 % \$ nm 85 %	September Currency Impact (1) (226.4) \$ (0.6) (34.3)	30, 2021 Constant Currency Revenues 7,641.4 1,708.4 1,453.9	25 % nm 80 %
Net sales Developed Markets\$ Greater China JANZ Emerging Markets	7,867.9 \$ 1,709.0 1,488.2	6,132.3 69.3	% Change 28 % \$ nm	September Currency Impact (1) (226.4) \$ (0.6)	30, 2021 Constant Currency Revenues 7,641.4 1,708.4	25 % nm
Net sales Developed Markets\$ Greater China JANZ	7,867.9 \$ 1,709.0 1,488.2	6,132.3 69.3 805.8	% Change 28 % \$ nm 85 %	September Currency Impact (1) (226.4) \$ (0.6) (34.3)	30, 2021 Constant Currency Revenues 7,641.4 1,708.4 1,453.9	25 % nm 80 %
Net sales Developed Markets\$ Greater China JANZ Emerging Markets	7,867.9 \$ 1,709.0 1,488.2 2,417.2 13,482.3	6,132.3 69.3 805.8 1,224.8	28 % \$ nm 85 % 97 %	September Currency Impact (1) (226.4) \$ (0.6) (34.3) (30.8)	30, 2021 Constant Currency Revenues 7,641.4 1,708.4 1,453.9 2,386.4	25 % nm 80 % 95 % 60 %

Currency impact is shown as unfavorable (favorable).

Amounts exclude intersegment revenue that eliminates on a consolidated basis.



⁽²⁾ The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period exchange rates, and in doing so shows the percentage change from 2021 constant currency net sales or revenues to the corresponding amount in the prior year.

For the three months ended September 30, 2021, other revenues in Developed Markets, JANZ, and Emerging Markets were approximately \$12.2 million, \$0.3 million, and \$3.6 million, respectively. For the nine months ended September 30, 2021, other revenues in Developed Markets, JANZ, and Emerging Markets were approximately \$46.7 million, \$1.3 million, and \$14.4 million, respectively.

Cost of Sales

	Three Months Ended September 30,		Nine months ended September 30,			
_		2021	- 2	2020	2021	2020
U.S. GAAP cost of sales	\$	2,962.5	\$	1,813.6 \$	9,515.6 \$	5,232.2
Deduct:						
Purchase accounting related amortization		(919.9)		(368.5)	(3,344.7)	(1,072.5
Acquisition related items		(4.5)		(9.4)	(8.0)	(11.5
Restructuring related costs		(151.3)		(8.7)	(399.5)	(17.6
Share-based compensation expense		(0.8)		(0.4)	(2.0)	(1.1
Other special items		(72.7)		(83.6)	(257.1)	(299.3
Adjusted cost of sales	\$	1,813.3	\$	1,343.0 \$	5,504.3 \$	3,830.2
Adjusted gross profit (a)	\$	2,723.3	\$	1,629.1 \$	8,040.4 \$	4,492.3
Adjusted gross margin (a)		60 %		55 %	59 %	54 %

⁽a) U.S. GAAP gross profit is calculated as total revenues less U.S. GAAP cost of sales. U.S. GAAP gross margin is calculated as U.S. GAAP gross profit divided by total revenues. Adjusted gross profit is calculated as total revenues less adjusted cost of sales. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.



R&D

	7	Three Months Ended September 30,		Nine months ended September 30,		
	:	2021	2020	2021	2020	
U.S. GAAP R&D	\$	152.1 \$	129.8 \$	483.9 \$	400.3	
Add / (Deduct):						
Acquisition related costs		(8.0)	(0.1)	(1.1)	(0.3)	
Restructuring and related costs		4.7	0.1	(11.9)	(0.3)	
Share-based compensation expense		(1.5)	(0.5)	(3.4)	(1.6)	
Other special items		(3.7)	(3.7)	(12.1)	(45.8)	
Adjusted R&D	\$	150.8 \$	125.6 \$	455.4 \$	352.3	
Adjusted R&D as % of total revenues		3 %	4 %	3 %	4 %	

SG&A

	Three Months	Ended	Nine Months	Ended
	Septembe	r 30,	September	r 30 ,
	2021	2020	2021	2020
U.S. GAAP SG&A\$	1,055.0 \$	658.4 \$	3,446.3 \$	1,983.2
Deduct:				
Acquisition related costs	(36.2)	(62.9)	(140.6)	(206.5
Restructuring and related costs	(23.1)	(5.7)	(330.1)	(29.0
Share-based compensation expense	(22.7)	(14.2)	(83.2)	(47.1
Other special items and reclassifications	(9.9)	(7.5)	(39.4)	(12.9
Adjusted SG&A	963.1 \$	568.1 \$	2,853.0 \$	1,687.7
Adjusted SG&A as % of total revenues	21 %	19 %	21 %	20 9



Total Operating Expenses

	Three Months Ended		Nine Months Ended		
	Septembe	r 30,	September 30,		
	2021	2020	2021	2020	
U.S. GAAP total operating expenses\$	1,216.5 \$	807.1 \$	3,985.5 \$	2,420.0	
Deduct:					
Litigation settlements and other contingencies, net	(9.4)	(18.9)	(55.3)	(36.5	
R&D adjustments	(1.3)	(4.2)	(28.5)	(48.0	
SG&A adjustments	(91.9)	(90.3)	(593.3)	(295.5	
Adjusted total operating expenses\$	1,113.9 \$	693.7 \$	3,308.4 \$	2,040.0	
Adjusted earnings from operations (a)\$	1,609.4 \$	935.4 \$	4,732.0 \$	2,452.3	

(a) U.S. GAAP earnings from operations is calculated as U.S. GAAP gross profit less adjusted total operating expenses. Adjusted earnings from operations is calculated as adjusted gross profit less adjusted total operating



Interest Expense

	Three Mon	ths E	Inded	Nine Months	Ended
	September 30, September 30,				30,
	2021		2020	2021	2020
J.S. GAAP interest expense\$	151.9	\$	117.3 \$	488.0 \$	353.4
dd / (Deduct):					
Interest expense related to clean energy investments	(0.1)		(0.9)	(0.4)	(3.0
Accretion of contingent consideration liability	(2.3)		(3.0)	(7.3)	(9.4
Amortization of premiums and discounts on long-term debt	17.1		-	51.6	
Other special items	(1.2)		(1.4)	(3.6)	(4.2
djusted interest expense\$	165.4	\$	112.0 \$	528.3 \$	336.8



Other Expenses

	Septembe	r 30,	September 30,		
<u> </u>	2021	2020	2021	2020	
U.S. GAAP other expense (income), net\$	5.8 \$	(7.5) \$	16.1 \$	24.6	
Add / (Deduct):					
Clean energy investments pre-tax loss (a)	(17.6)	(2.9)	(52.2)	(37.4	
Other items	2.3	-	2.3	16.4	
Adjusted other (income) expense\$	(9.5) \$	(10.4) \$	(33.8) \$	3.6	

Adjustment represents exclusion of activity related to Mylan's clean energy investments, the activities of which qualify for income tax credits under section 45 of the U.S. Internal Revenue Code of 1986, as amended.



Earnings Before Income Taxes and Income Tax Provision

	Three Months Ended		Nine Months Ended		
	Septembe	er 30,	September 30,		
<u> </u>	2021	2020	2021	2020	
U.S. GAAP earnings (loss) before income taxes \$	199.9 \$	241.6 \$	(460.5) \$	292.3	
Total pre-tax non-GAAP adjustments	1,253.6	592.4	4,698.1	1,819.6	
Adjusted earnings before income taxes <u>\$</u>	1,453.5 \$	834.0 \$	4,237.6 \$	2,111.9	
U.S. GAAP income tax (benefit) provision\$	(111.6) \$	55.9 \$	544.8 \$	46.4	
Adjusted tax expense	366.0	98.4	196.8	344.3	
Adjusted income tax provision <u>\$</u>	254.4 \$	154.3 \$	741.6 \$	390.7	
Adjusted effective tax rate	17.5 %	18.5 %	17.5 %	18.5 %	



Combined Adjusted EBITDA

(In millions)	Three months ended September 30, 2020	Nine months ended September 30, 2020
Upjohn - U.S. GAAP Income before taxes	\$ 533.8	\$ 2,350.2
Interest expense	112.5	223.6
Depreciation and amortization	81.7	237.5
Upjohn EBITDA	\$ 728.0	\$ 2,811.3
Other adjustments	102.5	(5.3)
Upjohn Adjusted EBITDA	\$ 830.5	\$ 2,806.0
Add: Mylan Adjusted EBITDA	1,009.7	2,639.0
Combined Adjusted EBITDA	\$ 1,840.2	\$ 5,445.0

